On December 9, Ganli Pharmaceutical announced that it had reached a research and development cooperation agreement with Jingtai Technology for innovative AI peptide drugs in the field of metabolic diseases and the use of AI technology platforms. According to the agreement, Ganli Pharmaceutical will focus on core unmet treatment needs in the field of metabolic diseases and accelerate the discovery and development process of novel peptide innovative drugs based on Jingtai Technology's AI peptide development platform.™

Zhitongcaijing · 12/09/2025 07:33
On December 9, Ganli Pharmaceutical announced that it had reached a research and development cooperation agreement with Jingtai Technology for innovative AI peptide drugs in the field of metabolic diseases and the use of AI technology platforms. According to the agreement, Ganli Pharmaceutical will focus on core unmet treatment needs in the field of metabolic diseases and accelerate the discovery and development process of novel peptide innovative drugs based on Jingtai Technology's AI peptide development platform.™